and various covariates may affect its dosing and pharmacokinetics. 67
68
Objective: To identify predictors of the PEGV dose required to normalize insulin-like growth factor I (IGF-69 I) levels during PEGV monotherapy and in combination with long-acting somatostatin analogues . 71
72
Design: Two retrospective cohorts (Rotterdam + Liège acromegaly survey (LAS), total n=188) were meta-73 analysed as a form of external replication to study the predictors of PEGV dosing in addition to LA-SSA, 74 the LAS (n=83) was used to study the predictors of PEGV monotherapy dosing. Multivariable regression 75 models were used to identify predictors of the PEGV dose required to normalize IGF-I levels. 76
77
Results: For PEGV dosing in combination with LA-SSA, IGF-I levels, weight, height and age, were 78 associated with the PEGV normalization dosage (p=<0.001, p=<0.001, p=0.028 and p=0.047, 79 respectively). Taken together, these characteristics predicted the PEGV normalization dose correctly in 80 63.3% of all patients within a range of + /-60 mg/week (21.3% within a range of + /-20 mg/week). For 81 monotherapy, only weight was associated with the PEGV normalization dose (p=<0.001) and predicted 82 this dosage correctly in 77.1% of all patients within a range of + /-60 mg/week (31.3% within a range of 83
Introduction
and data on pre-treatment determinants of the PEGV dosage required for biochemical disease control is 114 sparse. Currently, IGF-I levels are most commonly used during PEGV titration, which is in line with a 115 previous study from our group reporting a positive correlation between baseline IGF-I levels and the 116 PEGV dose required for normalization of IGF-I during combination treatment of 18) . 117
Other predictors that have been reported are GH levels, sex, body weight and previous radiotherapy 118 (19, 20) . Two studies previously reported about a GH receptor polymorphism lacking exon 3, which 119 seemed to have an influence as well during PEGV dosing (21, 22) . However more recent studies in larger 120 acromegaly cohorts clearly state that this polymorphism has no clinical effect on the PEGV response nor 121 the determination of the required PEGV dose (23) (24) (25) . 122
Given the importance of swift biochemical control in acromegaly but the lack of studies 123 investigating pre-treatment predictors we aimed to develop a multivariate regression model for 124 predicting the required PEGV dose to achieve normalization of IGF-I levels in acromegaly patients. 125
126

Materials & Methods
127
Cohorts description 128
Rotterdam cohort 138
Clinical and biochemical data were collected from acromegaly patients with elevated IGF-I levels (>1.2x 139 upper limit of normal (ULN)), after at least 6 months of the highest dose of LA-SSAs (octreotide LAR 30 140 mg or lanreotide Autogel 120 mg every 28 days). In this group, 27 acromegaly patients started with 25 141 mg PEGV weekly as co-treatment, while another 18 started with 40 mg PEGV weekly, and the last 67 142 patients started with a variable PEGV dose, guided by their baseline IGF-I levels. This variable PEGV 143 starting dose was based on one of our previous reports ( figure 2, (18) ). The formula to calculate the 144 PEGV dose is 4 + (IGF-I z-score during treatment with high dose LA-SSA*16) and was deducted from a 145 method described previously (18). This formula can only be used when IGF-I levels are elevated after a 146 period of at least 6 months of LA-SSA treatment. Intervals of dose adaptations were 6-8 weeks until a 147 controlled IGF-I level was achieved on two consecutive occasions. The subjects then visited our 148 outpatient clinic every 16 weeks. When the once weekly PEGV dose exceeded 80 mg per injection, 149 patients divided the dosage to two weekly injections. With weekly doses over 200 mg, subjects changed 150 administration intervals into daily injections or 5 injections per week. At each visit to our outpatient 151 clinic, standard measurements were performed including assessments of IGF-I levels. Permission from 152 the Institutional Review Board of the Erasmus Medical Center Rotterdam was obtained and all patients 153 gave their written informed consent. 154
155
LAS cohort 156
Acromegaly patients from the LAS database treated with PEGV were selected and divided in two groups; 157 PEGV in combination with LA-SSA and PEGV monotherapy. From the LAS-database, we were able to 158 select 141 potential patients using the combination treatment. We excluded 65 patients, because of two 159 reasons; 1) no IGF-I normalization during LA-SSA + PEGV treatment was achieved (n=16) and; 2) follow-160 up data during LA-SSA/PEGV-treatment were missing (n=49). The remaining patients (n=76) were 161 selected for this study. The same exclusion criteria applied for the PEGV monotherapy patients. We 162 were able to select 122 potential patients using PEGV monotherapy. We excluded 39 patients (no IGF-I 163 normalization during PEGV monotherapy was achieved (n=6) and follow-up data during PEGV-treatment 164 were missing (n=33)). The remaining patients (n=83) were selected for this study. The medical ethics 165 committee from the Liège University hospital approved the protocol, and was covering the other 166
European centers. 167
168
Hormone assays 169
In the Rotterdam cohort, the GH and IGF-I level measurements were assessed with the Immulite 2000 170 assay (DPC Biermann GmbH/Siemens, Fernwald, Germany), a solid-phase, enzyme-labeled 171 chemiluminescent immunometric assay, with an intra-assay variability of 6%, and an inter-assay 172 variability of 5-6% for GH and with an intra-assay variability of 2-5%, and an inter-assay variability of 3-173 7% for IGF-I. The IGF-I age and sex-adjusted reference ranges were used from an article by Elmlinger et 174 al. (27) . In the LAS cohort, containing acromegaly patients from several European hospitals, the GH and 175 IGF-I level measurements were assessed locally, and consequently performed with different assays. 176 Therefore, the IGF-I levels were chosen to be expressed as the upper limit of normal (ULN) of the 177 reference ranges used in the local hospitals. In this study, GH levels were measured as a single random 178 sample and expressed as absolute values. 179
180
Candidate predictors 181
Variables that were considered as possible predictors for PEGV normalization dosage were selected 182 based on the literature (8, (18) (19) (20) , biological plausibility, and availability of robust data ascertainment in 183 both cohorts and included: age at diagnosis, sex, weight, height, tumor size (micro vs. macroadenoma at 184 diagnosis), presence of diabetes mellitus, IGF-I levels (expressed as ULN), random GH levels and previous 185 treatment modalities (transsphenoidal surgery, radiotherapy and the duration of LA-SSA monotherapy 186 before the addition of PEGV). Weight, IGF-I levels (expressed as ULN) and random GH levels were 187 collected between 6 months before and at the time of PEGV-addition. Other data was collected at 188 baseline (as indicated), was fixed data in the patient's record, or was established during disease process. 189
190
Outcome 191 The outcome used in this study was the PEGV dose (mg/week) needed for the normalization of IGF-I 192 levels either during the addition to LA-SSA (highest tolerable dose) or as PEGV monotherapy. were analysed using Fisher's exact test. For subjects in which PEGV was added to LA-SSA therapy, the 198 distribution of the PEGV dose required for normalization of IGF-I levels was not comparable between 199 the two cohorts, therefore we meta-analyzed the data as a form of external replication. For all 200 regression models, log-transformation of the outcome variable (required PEGV dose) was performed to 201 normalize residuals and non-linearity was assessed utilizing restricted cubic splines with 3-4 knots. We 202 used univariable linear regression models to assess the association between each candidate predictor 203 and the required PEGV dose. The decision for linear regression models instead of multiple models for 204 the identification of predictors was based on Akaike information criterions and log-likelihood tests 205 comparing multilevel models with random intercepts and/or slope per cohort versus standard linear 206 regression correcting for cohort. To allow for optimal generalizability of effect estimates that predict the 207 required PEGV dose, we performed multivariable multilevel modelling with a random intercept per 208 cohort for the final model. We selected useful predictors using backward selection based on the change 209 in regression coefficients and residual explained variability of the model, with a p-value <0.20 as to keep 210 predictors liberally in the model. Other p-values are considered statistically significant when lower than 211 0.05 (two-tailed). For subjects switching from LA-SSA to PEGV monotherapy, we used univariable linear 212 regression models to assess the association between each potential predictor and the required PEGV 213 dose. We subsequently calculated the predicted normalization dosage for each subject using the 214 outcomes of the final (multivariable) regression models. In addition, we also calculated more 215 conservative and more progressive models to cope with potential under or overtreatment by adding or 216 subtracting the equivalent of 40 mg/week from the outcome of the regression formula. To cope with 217 (differentially) missing values of the candidate predictors, missing data on candidate predictors were 218 multiple imputed (five times). The imputation model included all candidate predictor variables, the 219 outcome variable and several relevant variables descriptive for the study subjects. There was no 220 difference between the original or any of the imputed datasets. All analyses were performed in each of 221 the completed datasets and final results were pooled. All statistical analyses were performed using 222 threshold from approximately 100 kg (figure 1), results were similar after adjustment for age and height 247 (data not shown). There was a negative linear association of age with PEGV normalization dosage and a 248 positive linear association of height with PEGV normalization dosage. In multivariable analyses, the 249 association of age and height were no longer statistically significant after adjustment for weight, yet age 250 did meet the pre-specified criteria of being added in the final model. Other potential predictors were 251 not associated with the PEGV normalization dosage (figure 1). 252 
Discussion
279
The PEGV dose required for normalization of IGF-I levels in acromegaly is highly variable and a wide 280 inter-individual variation in PEGV serum levels is observed despite identical PEGV dosage (28, 29) . 281
Previous studies suggest that this variability depends on disease activity and individual response to the 282 drug (8,16). Therefore, PEGV titration is a process that requires a tailored approach for each individual. 283 This is the first study that focuses on identifying predictors for PEGV dosing and developing a 284 multivariable model in order to predict the required PEGV dose to achieve normalization of IGF-I levels 285 in acromegaly patients. The main findings of this study are; 1) IGF-I, weight, height and age at diagnosis 286 are associated with the PEGV dose required for normalization of IGF-I levels in patients treated with LA-287 SSA combined with PEGV and; 2) that weight is associated with the PEGV dose required for 288 normalization of IGF-I levels in patients treated with PEGV monotherapy. 289
To the best of our knowledge, only one previous study has investigated determinants of the 290 PEGV dose needed for IGF-I normalization. Parkinson et al. observed that GH and IGF-I levels, sex, 291 weight and previous radiotherapy were associated with the PEGV dose required for disease control in 292 patients treated with PEGV monotherapy (n=118) (20). In our study, IGF-I xULN was the best predictor 293 for PEGV dosing, yet GH levels were not associated with the required PEGV dose. The most likely 294 explanation for this difference is the variability of the GH-assays. The study by Parkinson et al. used a 295 single assay for the measurement of all GH levels, while GH levels in our study were measured in several 296 local hospitals and thereby consequently measured by different GH-assays. This can lead to 297 measurement errors and a bias. Moreover, single GH has a limited clinical usefulness as it has a short 298 half-life and is pulsatile excreted into the bloodstream. Therefore random single measurements of GH 299 are less suitable as a biochemical marker for acromegaly in clinical practice. These aspects are less 300 prominent for IGF-I measurements, as they are expressed as the upper limit of normal and are less 301 sensitive to daily variations as compared to GH. Despite, the limitations of GH-measurement, we chose 302 to include and analyze these GH levels, because of its biological plausibility as a candidate predictor and 303 the intension that our prediction model is going to be used in multiple hospitals and consequently GH-304 measurements will be performed with several different assays. 305
The best predictor during combination treatment, besides IGF-I, is the patients weight before 306 the start of PEGV. Patients with a higher bodyweight, require a higher PEGV dosage, which is a logical 307 and expected phenomenon. However in our study a positive non-linear association was observed, 308 suggesting a threshold effect from approximately 100 kg body weight which remained similar after 309 correction for sex, age and IGF-I levels. A possible explanation for this effect threshold could be that 310 these patients have different disease activity and therefore have a different body composition, possibly 311 more fat mass. Former studies already reported an association between weight and PEGV dose titration 312 (19, 20, 30) . Future studies should investigate whether a clinical assessment of body composition (ratios 313 of lean vs. fat mass percentages) may improve the prediction of the PEGV dose required for biochemical 314
normalization. 315
Female gender is reported to have a better PEGV response with similar PEGV doses during PEGV 316 monotherapy, however this gender-difference was not statically significant anymore when PEGV doses 317 were expressed per kg body weight (19). Another study did observe that women needed a higher 318 average PEGV dose of 0.04 mg/kg/day during PEGV monotherapy (20). It has been speculated that sex 319 differences in PEGV pharmacokinetics may influence absorption, distribution and/or clearance of the 320 drug as well as the modulation of GH sensitivity by estrogens and fat (31-33). However, regardless of 321 weight differences, we could not confirm a sex difference in relation to the PEGV normalization dose 322 during our study both in patients treated with PEGV monotherapy and in combination with LA-SSA. 323
Opposite to patients treated with the combination therapy, we found that IGF-I was not a 324 predictor of PEGV dosing during PEGV monotherapy, despite its biological plausibility. This may be 325 explained by differences in the disease severity of patients in the combination versus monotherapy 326 groups, given that the LAS combination cohort requires a median PEGV dose of 210 mg/week on top of 327 the maximum LA-SSA dosage, while the LAS cohort treated with PEGV monotherapy required a median 328 dose of 105 mg/week. According to the literature, to achieve efficacy rates of more than 90% during 329 PEGV monotherapy, the average expected weekly dose is above 120-130 mg (12,34) . Studies about the 330 combination treatment reported PEGV doses that range between 60-140 mg weekly in addition to LA-331 SSA (normalization rates range between 67-97%) (8, 10, 35) . These data show that the LAS-monotherapy 332 group contains less severe acromegaly patients, while the LAS-combination treatment group contains 333 more severe acromegaly patients relative to data from the literature, presumed that the PEGV dose 334 represents disease severity. On the other hand, LA-SSA has a direct and an indirect effect, which results 335 in GH-independent decrease of IGF-I secretion (36,37). A Danish group observed that PEGV serum levels 336 increase by 20% when combined with LA-SSA (38). Besides dosing difference, it may be expected that 337 the use of two drug modalities is naturally more given to patients with more disease severity. 338
Additionally, IGF-I (xULN) levels before the addition of PEGV in both LAS cohorts treated with 339 monotherapy and combination treatment are higher. On the other hand, it should be take into account 340 the differences between the various IGF-I-assay's which were used in the different cohorts. 341
The PEGV doses of the LAS cohort required for IGF-I normalization were strikingly high 342 compared to the Rotterdam cohort. The distribution of normalization PEGV dosage were right skewed 343 as opposed to the normally distributed Rotterdam cohort. This most likely reflects the fact that the LAS 344 cohort represents the more severe cases in Europe, while the experience with PEGV in Rotterdam has 345 led to a relatively low threshold for prescribing PEGV in addition to LA-SSA. This may not directly be 346 linked to a difference in IGF-I levels before the addition of PEGV in our study, however LAS patients are 347 younger and are having more diabetes mellitus, which are characteristics of more severe acromegaly. 348
Another possible explanation could be the interest of the research group in Liège for genetic disorders 349 causing acromegaly, taking into account that the possible prevalence of a mutation in the aryl 350 hydrocarbon receptor interacting protein (AIP) gene, X-linked acrogigantism (X-LAG) and/or familial 351 isolated pituitary adenoma (FIPA) patients could be higher in this cohort. Despite these differences, we 352 found that a meta-analysis of both cohorts (as a form of external replication) performed well and also 353 the separate analyses per cohort showed the same effect directions. By combining both cohorts, the 354 results of this study are widely generalizable as this approach has led to a study population that reflects 355 a wide range of acromegaly patient that is eligible to start PEGV treatment. 356
This study was potentially limited by the retrospective design, which consequently led to missing 357 data. In order to cope with both differentially and randomly missing data, we used multiple imputation. 358
This study was also limited by the relative small sample size. However, this is expected given the low 359 prevalence of acromegaly as well as the fact that only a subset of acromegaly patients is treated with 360 LA-SSA in combination with PEGV. The Rotterdam cohort harbored exclusively patients that were 361 normalized by LA-SSA in combination with PEGV, as PEGV doses were up-titrated until normalization of 362 IGF-I levels were achieved. The exclusion of patients from the LAS cohort not normalized by LA-SSA and 363 PEGV (n=16, 8.5%) or PEGV alone (n=6, 7.2%) has remained limited. In order to overcome these 364 limitations and to replicate our results, prospective studies utilizing a multicenter set-up are required. 365
This model is designed for patients who are about to start PEGV treatment after failure of LA-366 SSA monotherapy. Furthermore, this study is not designed to predict PEGV overdosing, since PEGV 367 doses were increased until IGF-I levels were normalized. But this prediction model should be considered 368 as a useful clinical tool during PEGV dose titration, which can be time consuming over multiple 369 outpatient clinic visits, especially when a high PEGV dose is needed to control the disease. 370
371
Conclusion
372
This is the first study that focuses on identifying predictors for the PEGV dose required for disease 373 control in acromegaly and the development of a multivariate prediction model for the required PEGV 374 dose. The model is designed for patients who are about to start PEGV after failure of LA-SSA 375 monotherapy and could be used as a clinical guidance tool during the start of PEGV dose titration. In this 376 study, the PEGV dose needed for normalization of IGF-I levels in addition to LA-SSA is associated with 377 Table 2 . Multivariable analysis of final model to predict optimal PEGV dosing 545 546
As the outcome is not normally distributed, the model should be calculated as: е 
578
The conservative and progressive model were defined as the normal model minus or plus 40 mg/week, respectively. The 
